BofA analyst Koichi Mamegano upgraded Takeda Pharmaceutical to Buy from Neutral with a $20 price target. The company has made progress in paying down interest-bearing debt and has been active in acquiring candidates like TYK2 inhibitor TASK-279, the analyst tells investors in a research note. After having been a "value stock" for a long time, expansion of the company’s pipeline to support future growth will likely have positive share price implications, contends the firm.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TAK:
